1月28日，巨子生物(02367)盘中上涨5.06%，截至11:13，报57.15元/股，成交3949.92万元。
巨子生物主营业务为研发和生产功效性护肤品、医疗器械和功能性食品，核心技术是采用自有的合成生物学技术开发重组胶原蛋白和稀有人参皂苷等生物活性成分。公司拥有93项专利和专利申请，其重组胶原蛋白技术在中国是首个获得专利的，并曾两次获得重要的技术奖励。
截至2024年中报，巨子生物营业总收入25.4亿元、净利润9.83亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.